While colorectal cancer incidence has gone down among older people, incidence rates have steadily increased for people under age 50. Younger people are more likely to be diagnosed at a later stage and have unique challenges that come with facing cancer in their prime.
Immunotherapy combination treatments are the first choice for treating many advanced cancers, and more combinations are coming.
A nationwide survey found strong support for complementary therapies like massage and meditation, but also significant barriers to access.
Immunotherapies are poised to change care in advanced endometrial cancer, and more news selected by the editors of Cancer Today.
As we welcome spring, enjoy the latest round of editors’ picks selected by the editors of AACR’s 10 journals. Among this month’s highlights are an analysis of the racial/ethnic and sex-related differences in genomic...
Outside the lab, Frank McCormick, PhD, FAACR, is a racecar driver, nurturing a passion he developed decades ago. (“We all need hobbies, right?” he says with a grin.) Inside the lab, he uses a...
Physicians consider which patients are ideal for immunotherapy drug combinations.
Protein signatures in the blood could help guide physicians in choosing among different immunotherapy drugs.
Study results show stereotactic body radiation therapy could be added to standard care.
Theranostics offers the promise of combining diagnosis and treatment.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now